Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 24INDUSTRY 12NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Neoplasms 67Lymphoma 55Multiple Myeloma 54Breast Neoplasms 52Neoplasm Metastasis 48Lung Neoplasms 47Prostatic Neoplasms 46Ovarian Neoplasms 39Leukemia, Myeloid, Acute 39Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 33Pancreatic Neoplasms 29Glioma 28Lymphoma, Non-Hodgkin 26Sarcoma 25Urinary Bladder Neoplasms 24Carcinoma, Renal Cell 24Brain Neoplasms 24Neuroblastoma 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Stomach Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Small Cell Lung Carcinoma 17Colonic Neoplasms 17Burkitt Lymphoma 17Squamous Cell Carcinoma of Head and Neck 16

Interventions

trametinib 1omipalisib 1Vorinostat 1GSK2141795 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Uveal Melanoma × 90 days × Clear all
NCT01587352 2026-04-13

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Dermatologic

Uveal Melanoma

NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 13 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡